68Ga-AAZTA-093 PET/CT: First-in-human Study in Patients With Prostate Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:
• confirmed treated or untreated prostate cancer patients;
• 68Ga-AAZTA-093 and 68Ga-PSMA-11/68Ga-PSMA-617 PET/CT within 1 week;
• signed written consent.
Locations
Other Locations
China
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITING
Fuzhou
Contact Information
Primary
Weibing Miao, MD
miaoweibing@126.com
86-0591-87981618
Backup
Guochang Wang, MD
guochang1007@163.com
86-0591-87981619
Time Frame
Start Date: 2024-04-01
Estimated Completion Date: 2024-10-01
Participants
Target number of participants: 30
Treatments
Experimental: 68Ga-AAZTA-093 PET/ CT
Drug: 68Ga-AAZTA-093 Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
Experimental: 68Ga-PSMA-11/68Ga-PSMA-617 PET/ CT
Drug: 68Ga-PSMA-11/68Ga-PSMA-617 Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11/68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Fujian Medical University